| 產(chǎn)品編號 | bsm-52338R |
| 英文名稱 | VEGFR1 Recombinant Rabbit mAb |
| 中文名稱 | 血管內(nèi)皮生長因子受體1重組兔單抗 |
| 別 名 | Vascular endothelial growth factor receptor 1; VEGF-R1; VEGFR-1; VEGF Receptor 1; FLT-1; vascular permeability factor receptor; vascular endothelial growth factor receptor; vascular endothelial growth factor receptor-1; fms-related tyrosine kinase 1; vascular endothelial growth factor/vascular permeability factor receptor; AI323757; FLT; FLT1; sFlt1; VGFR1_HUMAN; VGFR1_MOUSE. |
| 研究領域 | 腫瘤 細胞生物 免疫學 發(fā)育生物學 神經(jīng)生物學 生長因子和激素 激酶和磷酸酶 細胞膜受體 細胞表面分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | 3A6 |
| 交叉反應 | Human,Mouse,Rat |
| 產(chǎn)品應用 | WB=1:1000-2000,IHC-P=1:50-200,IHC-F=1:50-200,IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 147 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞漿 細胞膜 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human VEGFR1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
VEGF Receptor 1 (also known as FLT) belongs to the src gene family and shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. The protein acts as a receptor for VEGF, VEGFB and PGF. An alternatively spliced form of the gene produces a soluble protein (sFlt1) which binds vascular endothelial growth factor (VEGF) with high affinity. sFlt1 has a higher affinity for VEGF indicating that it may function as an inhibitor in the VEGF response. VEGF Receptor 1 is specifically expressed in most vascular endothelial cells and peripheral blood monocytes. Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, and proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts. Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to the activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates PLCG1. Promotes phosphorylation of AKT1, PTK2/FAK1; YES1 and CBL. Subunit : Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR.Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1,PIK3R1, PLCG1 and PTPN11. Interacts with GNB2L1/RACK1. Identified in a complex with CBL and CD2AP. Subcellular Location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Endosome. Note=Autophosphorylation promotes ubiquitination and endocytosis；Isoform 2: Secreted；Isoform 3: Secreted；Isoform 4: Secreted；Isoform 5: Cytoplasm (Potential)；Isoform 6: Cytoplasm (Potential)；Isoform 7: Cytoplasm (Potential). Tissue Specificity: Detected in normal lung, but also in placenta,liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC). Post-translational modifications: N-glycosylated. Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation. Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG1. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG1. Phosphorylation at Tyr-1331 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 7 Ig-like C2-type (immunoglobulin-like)domains.Contains 1 protein kinase domain. SWISS: P17948 Gene ID: 2321 Database links: Entrez Gene: 2321 Human Entrez Gene: 14254 Mouse Omim: 165070 Human SwissProt: P17948 Human SwissProt: P35969 Mouse Unigene: 594454 Human Unigene: 389712 Mouse Unigene: 10239 Rat |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with VEGFR1 monoclonal antibody, unconjugated (bsm-52338R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
Paraformaldehyde-fixed, paraffin embedded Human Gastric Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by c
Paraformaldehyde-fixed, paraffin embedded Human Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Mouse Uterus; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Rat Uterus; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugation
Paraformaldehyde-fixed, paraffin embedded Mouse Placenta; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjuga
Paraformaldehyde-fixed, paraffin embedded Rat Placenta; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Mouse Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Rat Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugation
Paraformaldehyde-fixed, paraffin embedded Mouse Lung; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugation
Paraformaldehyde-fixed, paraffin embedded Rat Lung; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugation t
Paraformaldehyde-fixed, paraffin embedded Mouse Cerebrum; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjuga
Paraformaldehyde-fixed, paraffin embedded Rat Cerebrum; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R)at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R) at 1:200 overnight at 4°C, followed by c
Paraformaldehyde-fixed, paraffin embedded Human Ovarian Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R) at 1:200 overnight at 4°C, followed by
Paraformaldehyde-fixed, paraffin embedded Human Cervical Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R) at 1:200 overnight at 4°C, followed by
Paraformaldehyde-fixed, paraffin embedded Mouse Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R) at 1:200 overnight at 4°C, followed by conjugat
Paraformaldehyde-fixed, paraffin embedded Rat Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with VEGFR1 Monoclonal Antibody, Unconjugated(bsm-52338R) at 1:200 overnight at 4°C, followed by conjugatio
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
